SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma

(2019) Sara Gomes et al.   CANCER LETTERS

Mutant p53R175H promotes cancer initiation in the pancreas by stabilizing HSP70

(2019) Kishore Polireddy et al.   CANCER LETTERS

Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action

(2018) Bartosz Wawrzynow et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines

(2018) Matthias G.J. Baud et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells

(2018) Federica Alessandrini et al.   NEOPLASIA

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

(2018) Ramona Schulz-Heddergott et al.   Cancers

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Improving anticancer activity towards colon cancer cells with a new p53-activating agent

(2018) Liliana Raimundo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tumor suppressive role for kinases phosphorylating p53 in the DNA damage-induced apoptosis

(2018) Satomi Yogosawa et al.   CANCER SCIENCE

Small Molecules Targeting Mutant P53: A Promising Approach For Cancer Treatment

(2018) Elizabeth A. Lopes et al.   CURRENT MEDICINAL CHEMISTRY

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma

(2017) Jean-Luc Raoul et al.   EXPERT OPINION ON PHARMACOTHERAPY

DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties

(2017) Joana Soares et al.   Molecular Oncology

Systemic Therapy for Hepatocellular Carcinoma: 2017 Update

(2017) Masatoshi Kudo   ONCOLOGY

Alternative mechanisms of miR-34a regulation in cancer

(2017) Eva Slabáková et al.   Cell Death & Disease

Landscape of genomic alterations in hepatocellular carcinoma: current knowledge and perspectives for targeted therapies

(2017) Kévin Bévant et al.   HEPATOBILIARY SURGERY AND NUTRITION

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

(2016) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

Survivin in survival of hepatocellular carcinoma

(2016) Changqing Su   CANCER LETTERS

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

(2016) Muhammad S. Beg et al.   INVESTIGATIONAL NEW DRUGS

2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

(2016) Matthias R. Bauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis

(2015) Masatsugu Hiraki et al.   CHEMISTRY & BIOLOGY

Enantiopure Indolizinoindolones with in vitro Activity against Blood- and Liver-Stage Malaria Parasites

(2015) Nuno A. L. Pereira et al.   ChemMedChem

Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, and Hepatocellular Carcinoma

(2015) Mazen Noureddin et al.   Clinics in Liver Disease

Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53–MDM2 interaction

(2015) Joana Soares et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins

(2015) Joana Soares et al.   PHARMACOLOGICAL RESEARCH

Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule

(2015) Joana Soares et al.   Oncotarget

Systemic Delivery of a miR34a Mimic as a Potential Therapeutic for Liver Cancer

(2014) C. L. Daige et al.   MOLECULAR CANCER THERAPEUTICS

The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma

(2014) Yi Jin et al.   TUMOR BIOLOGY

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

Meta-Analysis: Prognostic Value of Survivin in Patients with Hepatocellular Carcinoma

(2013) Jin Long Liu et al.   PLoS One

Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress

(2013) Pei-Ming Yang et al.   Scientific Reports

Treatment of Hepatocellular Carcinoma: A Systematic Review

(2012) Shibo Lin et al.   Liver Cancer

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(2009) S. A. Bustin et al.   CLINICAL CHEMISTRY

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

(2009) J M R Lambert et al.   ONCOGENE

Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions

(2009) D Walerych et al.   ONCOGENE

miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells

(2008) Na Li et al.   CANCER LETTERS

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

(2008) Inki Kim et al.   NATURE REVIEWS DRUG DISCOVERY

Transcriptional control of human p53-regulated genes

(2008) Todd Riley et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

(2008) F. M. Boeckler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA